---
title: "Varegacestat (AL102) in Desmoid tumors: Economic impact on families"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Economic impact on families. Topics: Age and sex distribution: women of childbearing and working age; Age and sex at diagnosis in Danish registers; Impact on careers, family, and carers: NICE committee discussion; Parental role and dependence on family members; 10 further topics. 14 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/economic-impact-on-families"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Economic impact on families

<a id="heading-2.2.1.8.3"></a>

## 2.2.1.8.3 Economic Impact of Desmoid tumors on Families

<a id="topic-2.2.1.8.3-1"></a>

### Age and sex distribution: women of childbearing and working age

> “Additionally, the burden of DT is disproportionately borne by women of childbearing and working age, and because it is associated with low mortality and a relatively young patient population, it typically continues for decades.”

Source: [Kasper et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11166168/)

<a id="topic-2.2.1.8.3-2"></a>

### Age and sex at diagnosis in Danish registers

> “Of the 179 DT patients identified, 76% were female and the median patient age was 38 years at diagnosis (interquartile range: 31-50).”

Source: [Anneberg et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35121405/)

<a id="topic-2.2.1.8.3-3"></a>

### Impact on careers, family, and carers: NICE committee discussion

> “They highlighted the emotional impact and that many people with desmoid tumours experience anxiety and depression. They also explained that desmoid tumours can affect careers, relationships and social lives, and the ability to have a family. The committee acknowledged the significant impact on quality of life that desmoid tumours can have for people living with the condition and their families and carers.”
> “This means that people with desmoid tumours are expected to live with the tumour and the associated pain, loss of function and mobility and the impact on work and family life.”
> “In addition, the committee noted that desmoid tumours are more commonly diagnosed in younger people, particularly people of reproductive age.”
> “It noted that desmoid tumours can have a severe impact on carers' quality of life.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="topic-2.2.1.8.3-4"></a>

### Parental role and dependence on family members

> “DF patients also felt that their parental role was affected including difficulty breastfeeding, playing games with their children and depending on their partner or parent for childcare.”
> “Financial strain due to lost productivity and medical costs, including travelling costs to the hospital can lead to dependence on family members and have an adverse effect on patients’ social relationships.”

Source: [Husson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6373240/)

<a id="topic-2.2.1.8.3-5"></a>

### Family planning: Dutch focus groups

> “One participant reported that DTF restricted her from having another child, which had a major impact on her family.”
> “Another participant reported the feeling that he missed out on starting a family because of extensive treatments which started at a young age.”

Source: [Timbergen et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6244798/)

<a id="topic-2.2.1.8.3-6"></a>

### Family-related impacts reported in GODDESS concept elicitation interviews

| Impact | Frequency of mentions (n = 31) | Median disturbance rating (0 to 10) |
| --- | --- | --- |
| Concern for other family members | “20” | “6.25” |
| Worry over becoming pregnant | “7” | “6.00” |

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

<a id="topic-2.2.1.8.3-7"></a>

### Pregnancy and desmoid fibromatosis: international multicenter study

> “This international, multicenter, retrospective observational study included data from 157 women with DF, contributing 177 pregnancies.”
> “Among 177 pregnancies, Group A exhibited the highest rates of DF progression (68.7 % during pregnancy, 40.6 % postpartum), while Groups B and C had lower progression rates (9.5 % during pregnancy, 8.3 % postpartum). Active treatment was required in 5.6 % of cases. Spontaneous regression occurred in 23.7 % of pregnancies, particularly following progression. Obstetric complications were comparable to those in the general population.”
> “Individualized counseling is essential for managing risks of progression and recurrence, supporting informed fertility decisions. Referral to specialized centers is recommended to optimize DF management during family planning and pregnancy.”

Source: [Fiore et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40328165/)

<a id="topic-2.2.1.8.3-8"></a>

### Pregnancy-related desmoid fibromatosis: four sarcoma centers

> “Ninety-two women were included. Forty-four women (48%) had pregnancy-related DF (A + B), whereas 48 (52%) had a history of DF before conception (C + D).”
> “DF does not increase obstetric risk, and it should not be a contraindication to future pregnancy.”

Source: [Fiore et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24477160/)

<a id="topic-2.2.1.8.3-9"></a>

### Pregnancy-associated desmoid fibromatosis: Dutch multicenter study

> “Overall, 62 patients were included. The most common locations were abdominal wall (74%), pelvis (10%) and extremities (10%).”
> “Ten patients (16%) were diagnosed during pregnancy, while the remainder were diagnosed after pregnancy with a median time from delivery to diagnosis of 19 months (1-60). The frontline management was AS in 38 patients (61%) of whom 12 (33%) developed progressive disease and surgery in 23 patients (37%).”

Source: [Drabbe et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36404250/)

<a id="topic-2.2.1.8.3-10"></a>

### Recent pregnancy and risk of progression or relapse in the ALTITUDES cohort

> “A total of 242 patients (median age, 34.7 years) were included in the present study.”
> “Pregnancy occurred within 24 months before, at the time of, and after DF diagnosis in 33%, 5%, and 10% of the cases, respectively.”
> “After adjusting for DF location, tumor size, front-line treatment strategy, and hormonal contraception, we observed an increased risk of events occurring at 24 months after pregnancy [hazard ratio (HR) = 2.09, P = 0.018].”

Source: [Debaudringhien et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9588892/)

<a id="topic-2.2.1.8.3-11"></a>

### Fertility considerations across treatment options: NICE committee discussion

> “Patient experts highlighted that people with desmoid tumours face fertility challenges across the other treatment options, including chemotherapy. Menopause and fertility issues need to be considered regardless of which treatment is offered.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="topic-2.2.1.8.3-12"></a>

### Fertility preservation in familial adenomatous polyposis-associated desmoid tumours

> “The study included women with FAP-associated desmoid tumours who underwent fertility treatments at the authors' tertiary medical centre between the years 2011 and 2021.”
> “Overall, 17 women were identified suitable for this study. A total of 117 mature oocytes were vitrified for fertility preservation and 106 embryos were submitted to PGT-M. One patient returned to claim her cryopreserved oocytes, and five patients who underwent PGT-M embryo transfer reported three live births.”
> “Ovarian stimulation for women with desmoid tumours was characterized in some patients with an acceleration in tumour growth, regardless of the use of aromatase inhibitors.”

Source: [Fouks et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34429254/)

<a id="topic-2.2.1.8.3-13"></a>

### Oocyte cryopreservation before systemic therapy in young adults

> “With a peak incidence in young adulthood, desmoid tumors (DTs) often cause pain, loss of function, and diminished quality of life.”
> “Eleven young adult (YA) patients with DT who received nirogacestat were identified for the study. The median patient age was 26 years.”
> “Out of nine female patients, two elected to undergo oocyte cryopreservation prior to starting therapy.”

Source: [Rutherford et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42500920/)

<a id="topic-2.2.1.8.3-14"></a>

### Treatment schedule for children: Pediatric Oncology Group phase 2 study

> “To determine the efficacy and safety of using vinblastine (Vbl) and methotrexate (Mtx) in children with desmoid-type fibromatosis that is recurrent or not amenable to treatment with radiation or surgery.”
> “Patients were treated using Vbl (5 mg/m2/dose) and Mtx (30 mg/m2/dose), both administered by intravenous injection weekly for 26 weeks and every other week for an additional 26 weeks.”

Source: [Skapek et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17290057/)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
